Escherichia Coli; Infection, IntestinalEVENCT05153824
Study of the Ecological and Evolutionary Dynamics of Escherichia Coli in the Digestive Commensal Flora
An observational study of Escherichia Coli; Infection, Intestinal, run by Assistance Publique - Hôpitaux de Paris at 2 sites in France.
Trial summary
Escherichia coli (E. coli) poses a major public health problem. E. coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia. However, little is known about the dynamics of intestinal colonization of the human host. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Escherichia Coli; Infection, Intestinal
- How many people
- 200 participants
- Where
- 2 sitesFrance
- Study dates
- 2 Mar 2021to 2 Sep 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: First phase of the study: 50 healthy volonteers of both sexes Second phase of the study: 200 healthy volonteers of both sexes, ie 0 to 50 from the pilot phase + 150 to 200 new subjects, depending on the number of volunteers in the pilot phase who wish to continue.
Who may be able to join
- healthy volunteer of both sexes between the ages of 18 and 65 years old included
- subject considered healthy after a thorough general examination (interrogation, physical examination)
- subject with normal transit with usually one molded saddle per day
- BMI between 18.5 and 35 kg / m² included
Who cannot join
- Subject living in an institution
- Known immunosuppression (HIV, concomitant immunosuppressive therapy, chemotherapy, long-term corticosteroids regardless of the dose> 2 weeks in the last 6 months)
- Chronic gastrointestinal illness (Chronic Hemorrhagic Recto-colitis, Crohn's Disease)
- Any digestive resection except appendectomy and resection of polyps
- Subject with a history (s) of bacteremia
- Subject protected by law under guardianship or curator-ship
Show all 11Show fewer
- Pregnant or lactating woman
- Subject deprived of liberty under judicial duress
- Lack of affiliation to a social security scheme
- Patient on State Medical Aid
- Absence of signed consent before entering the study
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France2 sites, 2 recruiting
- Recruiting
Bichat Claude Bernard Hospital
Paris, 75018
Xavier Duval, MD, PhD, 01 40 25 71 48, xaviel.duval@aphp.fr
- Recruiting
Bichat Hospital, Clinical Investigation Center
Paris, 75018
About this study
Escherichia coli (E. coli) poses a major public health problem. E. coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia. However, little is known about the dynamics of intestinal colonization of the human host. Understanding the dynamics of colonization is crucial because selection for the major traits of E. coli is antibiotic resistance and virulence (the propensity to cause infection) works in commensalism, in the gut, not in infections. This study will make possible for the first time to study the colonization dynamics of E. coli in a large healthy host population.
The main objective is to quantify the succession (gain, loss or replacement) of E. coli strains in the gut microbiota in healthy volunteers and how it depends on the properties of the host and the bacteria. This study will thus provide a better understanding of the E. Coli's epidemiological dynamics and the development of certain traits such as antibiotic resistance.
Read more
To reach this goal, the study will take place in two successive phases :
A first pilot phase will first be conducted with 50 healthy volunteers. During this pilot phase, a stool sample will be taken. The strains isolated during this pilot phase will be sequenced, making possible to characterize the strains present and the strains' possible changes between two stool samples. Succession rates will be estimated. The optimal sampling rate that maximizes accuracy in estimating succession rates will be identified and retained for the second phase.
A second phase, a prospective cohort study will also be conducted in 200 healthy volunteers.
During this second phase, healthy volunteers who participated in the first phase will be able to continue their participation and new volunteers will be selected. The healthy volunteers included in the prospective cohort study will be followed up with visits and stool samples which will be defined according to the results of the pilot phase.
Read the detailed description
Escherichia Coli poses a major public health problem. E. Coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia. However, little is known about the dynamics of intestinal colonization of the human host. Understanding the dynamics of colonization is crucial because selection for the major traits of E. coli is antibiotic resistance and virulence (the propensity to cause infection) works in commensalism, in the gut, not in infections. This study will make possible for the first time to study the colonization dynamics of E. coli in a large healthy host population. In particular, we will quantify how the loss or gain of certain strains in the intestine depends on the properties of the host and the bacteria. This study will thus provide a better understanding of the E. coli's epidemiological dynamics and the development of certain traits such as antibiotic resistance.
Main objective and criterion The main objective of this research is to quantify the succession (gain, loss or replacement) of E. coli strains in the gut microbiota in healthy volunteers.
Secondary objectives and criteria The secondary objective is to study the intra-host evolution of E. coli by focusing on the evolution of clones colonizing the same host for long periods of time. This makes possible to understand whether the intra-host evolution is dominated by mutations conferring a selective advantage (such as resistance to antibiotics) or on the contrary neutral mutations (having no effect on the proteins produced).
Population The two phases of this study will be conducted in healthy adults of both sexes. Healthy volunteers will be recruited from the file of healthy volunteers for biomedical research at the Clinical Investigation Center (CIC) of the Bichat - Claude Bernard hospital group.
Practical procedure This research will take place in two successive phases: A first so-called pilot phase will first be conducted with healthy volunteers. During this pilot phase, 50 healthy volunteers will be selected and followed every 2 weeks for a stool sample. The pilot phase will include 10 visits for a total duration of 18 weeks per volunteer. The strains isolated during this pilot phase will be sequenced, making possible to characterize the strains present and the possible changes of strains between two stool samples. Succession rates will be estimated. The results of this phase identify the optimal sampling rate that maximizes accuracy in estimating succession rates. This will be retained for the second phase.
The participation of the volunteers included in the pilot study will be broken down into 2 stages :
- a stage of volunteers'selection at the CIC: each volunteer will have a clinical examination to ensure their eligibility for participation in the research. He must meet all the selection criteria on the day of this visit and sign the collection consent;
- an 18-week follow-up period during which the volunteers go to the CIC to deposit stool samples every two weeks for 18 weeks (corresponding to 10 visits).
A second phase, a prospective cohort study will also be conducted in healthy volunteers. During this second phase, healthy volunteers who participated in the first phase will be able to continue their participation and new volunteers will be selected.The healthy volunteers included in the prospective cohort study will be followed up with visits and stool samples which will be defined according to the results of the pilot phase for a period of 8 to 144 weeks maximum.
The participation of volunteers included in the cohort study will be broken down into 2 stages:
- a stage for the selection of volunteers at the CIC (V1): all participants will have a clinical examination to ensure their eligibility for participation in the research. They must meet all the inclusion criteria available on the day of this visit and sign the collection consent.
- a follow-up period of 144 weeks maximum: 8 follow-up visits with a rhythm of 1 to 18 weeks, ie 8 to 144 weeks max. The volunteers will go to the CIC to deposit stool samples at each of the 8 planned visits. The schedule for these 8 visits will be determined based on the results of the pilot phase.
Number of subjects selected First phase: 50 subjects Second phase: 200 subjects, ie 0 to 50 from the pilot phase + 150 to 200 new subjects, depending on the number of volunteers in the pilot phase who wish to continue.
Number of centers Monocentric national study: Clinical Investigation Center of the Bichat - Claude Bernard hospital group.
Research calendar
- First phase:
- duration of inclusion: 6 months (26 weeks)
- duration of participation (treatment + follow-up): 18 weeks
- total duration: 44 weeks
- Second phase:
- duration of inclusion: 18 months (78 weeks)
- duration of participation (treatment + follow-up): 8 to 144 weeks
- total duration: 86 to 222 weeks
Statistical analysis To estimate the rates of gain, loss and replacement of E. coli strains depending on host and bacterial factors, statistical analyzes will be performed using R software within the French Institute for Health and Medical Research U722: first on the 50 volunteers in the pilot phase, which will allow a first estimate of these rates and define thus the optimal sampling schedule for the prospective cohort phase, then on the 200 volunteers of this second phase.
The statistical model used for the two analyzes will describe the dynamics of host colonization. We will assume that the host colonization state follows a discrete-state Markov chain in continuous time. This mathematical model describes the transitions between the different possible states, by strain gain, strain loss, and strain replacement within the host. It calculates the probability of the data obtained knowing the parameters (strain gains, strain loss, strain replacement) and therefore the likelihood (the probability of the data knowing the model). From the likelihood, the parameters can be estimated by maximum likelihood methods.
Quantitatively, the parameters will be estimated by maximum likelihood and the precision will be quantified by confidence intervals obtained by the likelihood profile method.
The dependence of the gain, loss and replacement rates on several host or bacterial variables will also be estimated. The significance of the effect of a variable on the gain, loss and replacement rates will be tested by model comparison: the models will be adjusted by maximum likelihood. The comparison of models will be done by likelihood ratio test.
First, the factors that are suspected a priori to be important for transition rates will be tested. The level of significance of these factors will be corrected for multiple tests (Bonferroni correction). In a second step, the impact of all the elements of the genome will be analyzed in an exploratory way (genome-wide association study).
- Conditions
- Escherichia Coli; Infection, Intestinal
- Keywords
- Escherichia coli, Gut microbiota, Commensalism, Antibiotic resistance
- Medical subject headings
- Escherichia coli Infections, Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers | Healthy volunteers |
What is being measured
The primary outcome is the main question the study is designed to answer.
Estimation of rates of gain, loss and replacement of E. coli strains
We will estimate the rates of gain, loss and replacement of E. coli strains by fitting a discrete state, continuous time Markov model to the data on strain colonisation status.
Measured: 6 years
Secondary outcomes (1)
Identification of mutations occurring within-host by reconstruction of the genomes of Escherichia coli and comparative analysis of the genomes of the different time points within a single host
We will reconstruct whole genomes of E. coli for individuals presenting long-term colonisation. We will align these genomes and identify point mutations or other genomic changes. We will characterise these changes (synonymous, non-synonymous) and evaluate population genetic parameters.
Measured: 6 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Dec 2021
- Study start2 Mar 2021
- Primary completion2 Mar 2024 (estimated)
- Study completion2 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Escherichia Coli; Infection, IntestinalStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05153824
- Sponsor's protocol ID
- APHP200169
- Acronym
- EVE
- Status last verified
- Apr 2023
- First submitted
- 9 Dec 2021
- Last updated
- 10 Apr 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Apr 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Ecological and Evolutionary Dynamics of Escherichia Coli in the Digestive Commensal Flora
- ClinicalTrials.gov ID
- NCT05153824
- Acronym / sponsor ID
- EVE / APHP200169
- Conditions
- Escherichia Coli; Infection, Intestinal
- Keywords
- Escherichia coli, Gut microbiota, Commensalism, Antibiotic resistance
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 2 Mar 2021 (actual)
- Primary completion
- 2 Mar 2024 (estimated)
- Study completion
- 2 Sep 2027 (estimated)
- First posted
- 10 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Escherichia coli (E. coli) poses a major public health problem. E. coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia. However, little is known about the dynamics of intestinal colonization of the human host. Understanding the dynamics of colonization is crucial because selection for the major traits of E. coli is antibiotic resistance and virulence (the propensity to cause infection) works in commensalism, in the gut, not in infections. This study will make possible for the first time to study the colonization dynamics of E. coli in a large healthy host population.
The main objective is to quantify the succession (gain, loss or replacement) of E. coli strains in the gut microbiota in healthy volunteers and how it depends on the properties of the host and the bacteria. This study will thus provide a better understanding of the E. Coli's epidemiological dynamics and the development of certain traits such as antibiotic resistance.
To reach this goal, the study will take place in two successive phases :
A first pilot phase will first be conducted with 50 healthy volunteers. During this pilot phase, a stool sample will be taken. The strains isolated during this pilot phase will be sequenced, making possible to characterize the strains present and the strains' possible changes between two stool samples. Succession rates will be estimated. The optimal sampling rate that maximizes accuracy in estimating succession rates will be identified and retained for the second phase.
A second phase, a prospective cohort study will also be conducted in 200 healthy volunteers.
During this second phase, healthy volunteers who participated in the first phase will be able to continue their participation and new volunteers will be selected. The healthy volunteers included in the prospective cohort study will be followed up with visits and stool samples which will be defined according to the results of the pilot phase.
Detailed description
Escherichia Coli poses a major public health problem. E. Coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia. However, little is known about the dynamics of intestinal colonization of the human host. Understanding the dynamics of colonization is crucial because selection for the major traits of E. coli is antibiotic resistance and virulence (the propensity to cause infection) works in commensalism, in the gut, not in infections. This study will make possible for the first time to study the colonization dynamics of E. coli in a large healthy host population. In particular, we will quantify how the loss or gain of certain strains in the intestine depends on the properties of the host and the bacteria. This study will thus provide a better understanding of the E. coli's epidemiological dynamics and the development of certain traits such as antibiotic resistance.
Main objective and criterion The main objective of this research is to quantify the succession (gain, loss or replacement) of E. coli strains in the gut microbiota in healthy volunteers.
Secondary objectives and criteria The secondary objective is to study the intra-host evolution of E. coli by focusing on the evolution of clones colonizing the same host for long periods of time. This makes possible to understand whether the intra-host evolution is dominated by mutations conferring a selective advantage (such as resistance to antibiotics) or on the contrary neutral mutations (having no effect on the proteins produced).
Population The two phases of this study will be conducted in healthy adults of both sexes. Healthy volunteers will be recruited from the file of healthy volunteers for biomedical research at the Clinical Investigation Center (CIC) of the Bichat - Claude Bernard hospital group.
Practical procedure This research will take place in two successive phases: A first so-called pilot phase will first be conducted with healthy volunteers. During this pilot phase, 50 healthy volunteers will be selected and followed every 2 weeks for a stool sample. The pilot phase will include 10 visits for a total duration of 18 weeks per volunteer. The strains isolated during this pilot phase will be sequenced, making possible to characterize the strains present and the possible changes of strains between two stool samples. Succession rates will be estimated. The results of this phase identify the optimal sampling rate that maximizes accuracy in estimating succession rates. This will be retained for the second phase.
The participation of the volunteers included in the pilot study will be broken down into 2 stages :
- a stage of volunteers'selection at the CIC: each volunteer will have a clinical examination to ensure their eligibility for participation in the research. He must meet all the selection criteria on the day of this visit and sign the collection consent;
- an 18-week follow-up period during which the volunteers go to the CIC to deposit stool samples every two weeks for 18 weeks (corresponding to 10 visits).
A second phase, a prospective cohort study will also be conducted in healthy volunteers. During this second phase, healthy volunteers who participated in the first phase will be able to continue their participation and new volunteers will be selected.The healthy volunteers included in the prospective cohort study will be followed up with visits and stool samples which will be defined according to the results of the pilot phase for a period of 8 to 144 weeks maximum.
The participation of volunteers included in the cohort study will be broken down into 2 stages:
- a stage for the selection of volunteers at the CIC (V1): all participants will have a clinical examination to ensure their eligibility for participation in the research. They must meet all the inclusion criteria available on the day of this visit and sign the collection consent.
- a follow-up period of 144 weeks maximum: 8 follow-up visits with a rhythm of 1 to 18 weeks, ie 8 to 144 weeks max. The volunteers will go to the CIC to deposit stool samples at each of the 8 planned visits. The schedule for these 8 visits will be determined based on the results of the pilot phase.
Number of subjects selected First phase: 50 subjects Second phase: 200 subjects, ie 0 to 50 from the pilot phase + 150 to 200 new subjects, depending on the number of volunteers in the pilot phase who wish to continue.
Number of centers Monocentric national study: Clinical Investigation Center of the Bichat - Claude Bernard hospital group.
Research calendar
- First phase:
- duration of inclusion: 6 months (26 weeks)
- duration of participation (treatment + follow-up): 18 weeks
- total duration: 44 weeks
- Second phase:
- duration of inclusion: 18 months (78 weeks)
- duration of participation (treatment + follow-up): 8 to 144 weeks
- total duration: 86 to 222 weeks
Statistical analysis To estimate the rates of gain, loss and replacement of E. coli strains depending on host and bacterial factors, statistical analyzes will be performed using R software within the French Institute for Health and Medical Research U722: first on the 50 volunteers in the pilot phase, which will allow a first estimate of these rates and define thus the optimal sampling schedule for the prospective cohort phase, then on the 200 volunteers of this second phase.
The statistical model used for the two analyzes will describe the dynamics of host colonization. We will assume that the host colonization state follows a discrete-state Markov chain in continuous time. This mathematical model describes the transitions between the different possible states, by strain gain, strain loss, and strain replacement within the host. It calculates the probability of the data obtained knowing the parameters (strain gains, strain loss, strain replacement) and therefore the likelihood (the probability of the data knowing the model). From the likelihood, the parameters can be estimated by maximum likelihood methods.
Quantitatively, the parameters will be estimated by maximum likelihood and the precision will be quantified by confidence intervals obtained by the likelihood profile method.
The dependence of the gain, loss and replacement rates on several host or bacterial variables will also be estimated. The significance of the effect of a variable on the gain, loss and replacement rates will be tested by model comparison: the models will be adjusted by maximum likelihood. The comparison of models will be done by likelihood ratio test.
First, the factors that are suspected a priori to be important for transition rates will be tested. The level of significance of these factors will be corrected for multiple tests (Bonferroni correction). In a second step, the impact of all the elements of the genome will be analyzed in an exploratory way (genome-wide association study).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers | – | –Healthy volunteers |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- First phase of the study: 50 healthy volonteers of both sexes Second phase of the study: 200 healthy volonteers of both sexes, ie 0 to 50 from the pilot phase + 150 to 200 new subjects, depending on the number of volunteers in the pilot phase who wish to continue.
Key inclusion criteria (4 listed)
- healthy volunteer of both sexes between the ages of 18 and 65 years old included
- subject considered healthy after a thorough general examination (interrogation, physical examination)
- subject with normal transit with usually one molded saddle per day
- BMI between 18.5 and 35 kg / m² included
Key exclusion criteria (11 listed)
- Subject living in an institution
- Known immunosuppression (HIV, concomitant immunosuppressive therapy, chemotherapy, long-term corticosteroids regardless of the dose> 2 weeks in the last 6 months)
- Chronic gastrointestinal illness (Chronic Hemorrhagic Recto-colitis, Crohn's Disease)
- Any digestive resection except appendectomy and resection of polyps
- Subject with a history (s) of bacteremia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Estimation of rates of gain, loss and replacement of E. coli strains
Time frame: 6 years
We will estimate the rates of gain, loss and replacement of E. coli strains by fitting a discrete state, continuous time Markov model to the data on strain colonisation status.
1 secondary outcome
Identification of mutations occurring within-host by reconstruction of the genomes of Escherichia coli and comparative analysis of the genomes of the different time points within a single host
Time frame: 6 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Apr 2023.
- Individual participant dataSharing planned: No
Related trials for Escherichia Coli; Infection, Intestinal
Active, not recruitingPhase 1/2
Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease
Crohn Disease
Recruiting
Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Treatment in Rectal Cancers
Rectal Cancer
Active, not recruitingPhase 3
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Human Papillomavirus Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Escherichia Coli; Infection, Intestinal, run by Assistance Publique - Hôpitaux de Paris at 2 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xavier M DUVAL, MD, PhD (+33 (0)1 40 25 71 48, xavier.duval@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Estimation of rates of gain, loss and replacement of E. coli strains (time frame: 6 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Apr 2023.